Amgen Q1 2024 Financials: Product Sales and Balance Sheet Details
Ticker: AMGN · Form: 10-Q · Filed: 2024-05-03T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, earnings, balance-sheet
Related Tickers: AMGN
TL;DR
Amgen's Q1 2024 10-Q is out, showing product sales and balance sheet details. Check it for the latest financials.
AI Summary
Amgen Inc. reported its first quarter 2024 results for the period ending March 31, 2024. The company's filing details its financial performance, including product sales and other revenue streams, and provides balance sheet information as of March 31, 2024, and December 31, 2023. Key financial components like common stock, retained earnings, and accumulated other comprehensive income are presented for these periods.
Why It Matters
This filing provides investors with a snapshot of Amgen's financial health and operational performance in early 2024, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags or significant new risks highlighted.
Key Numbers
- 2024-03-31 — Balance Sheet Date (End of Q1 2024)
- 2023-12-31 — Previous Balance Sheet Date (End of Q4 2023)
- 2024-01-01 — Quarter Start Date (Beginning of Q1 2024)
- 2023-01-01 — Prior Year Quarter Start Date (Beginning of Q1 2023)
Key Players & Entities
- AMGEN INC (company) — Filer
- 20240331 (date) — Period of Report
- 20240503 (date) — Filing Date
- ONE AMGEN CENTER DRIVE (address) — Business Address
- THOUSAND OAKS (location) — City
- CA (location) — State
- 91320 (zip_code) — Business Zip Code
- 0000318154 (company_id) — Central Index Key
FAQ
What were Amgen's product sales for the first quarter of 2024?
The filing indicates product sales for the period January 1, 2024, to March 31, 2024, under the 'us-gaap:ProductMember' and 'us-gaap:ProductAndServiceOtherMember' tags, with comparative data for the same period in 2023.
What is the reported retained earnings as of March 31, 2024?
The filing includes 'us-gaap:RetainedEarningsMember' for March 31, 2024, and also provides the value for the period January 1, 2024, to March 31, 2024.
What is the company's fiscal year end?
Amgen's fiscal year ends on December 31.
What is the filing date of this 10-Q report?
This 10-Q report was filed on May 3, 2024.
What is the SEC file number for Amgen?
Amgen's SEC file number is 001-37702.
From the Filing
0000318154-24-000020.txt : 20240503 0000318154-24-000020.hdr.sgml : 20240503 20240502192757 ACCESSION NUMBER: 0000318154-24-000020 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240503 DATE AS OF CHANGE: 20240502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 24910329 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 10-Q 1 amgn-20240331.htm 10-Q amgn-20240331 0000318154 false 2024 Q1 12/31 http://fasb.org/srt/2023#PartnershipInterestMember http://fasb.org/srt/2023#PartnershipInterestMember 0000318154 2024-01-01 2024-03-31 0000318154 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000318154 amgn:A2.00SeniorNotesDue2026Member 2024-01-01 2024-03-31 0000318154 2024-04-29 xbrli:shares 0000318154 us-gaap:ProductMember 2024-01-01 2024-03-31 iso4217:USD 0000318154 us-gaap:ProductMember 2023-01-01 2023-03-31 0000318154 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-03-31 0000318154 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-03-31 0000318154 2023-01-01 2023-03-31 iso4217:USD xbrli:shares 0000318154 2024-03-31 0000318154 2023-12-31 0000318154 us-gaap:CommonStockMember 2023-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-12-31 0000318154 us-gaap:RetainedEarningsMember 2023-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000318154 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000318154 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000318154 us-gaap:CommonStockMember 2024-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-03-31 0000318154 us-gaap:RetainedEarningsMember 2024-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000318154 us-gaap:CommonStockMember 2022-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-12-31 0000318154 us-gaap:RetainedEarningsMember 2022-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000318154 2022-12-31 0000318154 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000318154 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000318154 us-gaap:CommonStockMember 2023-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-03-31 0000318154 us-gaap:RetainedEarningsMember 2023-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000318154 2023-03-31 amgn:segment 0000318154 amgn:HorizonTherapeuticsMember 2023-10-06 0000318154 amgn:HorizonTherapeuticsMember 2023-10-06 2023-10-06 0000318154 amgn:HorizonTherapeuticsMember 2024-01-01 2024-03-31 0000318154 us-gaap:DevelopedTechnologyRightsMember amgn:HorizonTherapeuticsMember 2023-10-06 0000318154 us-gaap:DevelopedTechnologyRightsMember amgn:HorizonTherapeuticsMember 2023-10-06 2023-10-06 0000318154 amgn:HorizonTherapeuticsMember 2024-03-31 0000318154 amgn:HorizonTherapeuticsMember 2023-01-01 2023-03-31 amgn:Segment 0000318154 amgn:ProliaMember country:US 2024-01-01 2024-03-31 0000318154 us-gaap:NonUsMember amgn:ProliaMember 2024-01-01 2024-03-31 0000318154 amg